Mary M. Rozenman Sells 25,000 Shares of Aimmune Therapeutics Inc. (AIMT) Stock
Aimmune Therapeutics Inc. (NASDAQ:AIMT) insider Mary M. Rozenman sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $16.80, for a total transaction of $420,000.00. Following the completion of the sale, the insider now directly owns 25,000 shares of the company’s stock, valued at approximately $420,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Aimmune Therapeutics Inc. (NASDAQ:AIMT) opened at 16.55 on Friday. The stock’s market capitalization is $699.30 million. The company’s 50-day moving average is $15.53 and its 200 day moving average is $13.65. Aimmune Therapeutics Inc. has a one year low of $9.77 and a one year high of $22.01.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.01. Equities analysts expect that Aimmune Therapeutics Inc. will post ($1.75) EPS for the current year.
A number of hedge funds have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. boosted its stake in shares of Aimmune Therapeutics by 94.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 51,994 shares of the company’s stock valued at $563,000 after buying an additional 25,278 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Aimmune Therapeutics by 4.5% in the second quarter. American Century Companies Inc. now owns 98,261 shares of the company’s stock valued at $1,063,000 after buying an additional 4,201 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Aimmune Therapeutics by 116.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 20,796 shares of the company’s stock valued at $225,000 after buying an additional 11,179 shares in the last quarter. Highbridge Capital Management LLC acquired a new stake in shares of Aimmune Therapeutics during the second quarter valued at about $230,000. Finally, Parametric Portfolio Associates LLC boosted its stake in shares of Aimmune Therapeutics by 23.4% in the second quarter. Parametric Portfolio Associates LLC now owns 48,270 shares of the company’s stock valued at $522,000 after buying an additional 9,156 shares in the last quarter. 68.87% of the stock is owned by institutional investors.
AIMT has been the subject of several analyst reports. Wedbush reissued an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research note on Monday, June 13th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $38.00 target price on shares of Aimmune Therapeutics in a research report on Tuesday, June 14th. Zacks Investment Research lowered shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 19th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating and set a $35.00 target price on shares of Aimmune Therapeutics in a research report on Friday, August 19th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $32.20.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.